WHO Pharmaceuticals Newsletter 1998, No. 09&10
(1998; 23 pages)
Índice de contenido
Abrir esta carpeta y ver su contenidoRegulatory decisions
Abrir esta carpeta y ver su contenidoDrug surveillance
Cerrar esta carpetaNew developments
Ver el documentoFomepizole - approved as an antidote in ethylene glycol poisoning: USA
Ver el documentoInfliximab - approved for Crohn’s disease: USA
Ver el documentoLeflunomide - oral treatment approved for active rheumatoid arthritis: USA
Ver el documentoLepirudin - approved for heparin-associated thrombocytopenia: UK
Ver el documentoOral contraceptives - approved for emergency use: USA
Ver el documentoRotavirus vaccine - approved to help prevent rotaviral disease: USA
Ver el documentoThalidomide - approved for use in leprosy: USA
Ver el documentoNew indications
Ver el documentoNew formulations
Ver el documentoNewly approved products
Abrir esta carpeta y ver su contenidoMedical devices
Abrir esta carpeta y ver su contenidoGeneral information
Abrir esta carpeta y ver su contenidoMedication errors
Abrir esta carpeta y ver su contenidoVeterinary medicine
 

Rotavirus vaccine - approved to help prevent rotaviral disease: USA

United States of America. The Food and Drug Administration has approved the first vaccine (Rotashield: Wyeth Ayerst) to help prevent rotaviral disease, the most common cause of severe diarrhoea and vomiting in infants in the United States.

The vaccine is approved for the immunization of infants and is given orally in a three- dose schedule at 2, 4 and 6 months, when most other childhood vaccines are given. It is not currently recommended to start the vaccination schedule in infants over 6 months.

The most common adverse reactions include moderate fever, increased irritability, and decreased appetite and activity, all within five days of vaccination.

Reference: HHS News P98-24 dated 31 August 1998.

Ir a la sección anterior Ir a la siguiente sección
 

Última actualización: le 3 mayo 2013